Rule will make permanent the temporary waivers easing access to buprenorphine via telehealth that began during the COVID-19 ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...

A doctor in Normal talks to WGLT about the American Academy of Sleep Medicine's updates on recommended treatments of restless ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Digital mental health platforms were supposed to expand access for the neediest patients. Researchers say that hasn’t ...

Proteins made using machine learning successfully bind snake toxins — plus, Earth’s temperature breaks a significant climate ...

The largest and most diverse genetic study of depression has identified 300 new genetic risk factors for the condition across ...

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectivelySunosi preliminary 4Q and full year ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.